Literature DB >> 23010905

Targeted screening as a tool for the early detection of chronic Q fever patients after a large outbreak.

M C A Wegdam-Blans1, R A Stokmans, J H T Tjhie, J M Korbeeck, M P Koopmans, S M A A Evers, P H van der Voort, J A W Teijink.   

Abstract

In the aftermath of the Dutch Q fever outbreak, an increasing number of patients are being diagnosed with chronic Q fever. Most of these patients are unaware of being infected with Coxiella burnetii, the causative agent of Q fever. To find patients in an earlier, asymptomatic stage, a targeted screening strategy (TSS) for patients with risk factors for chronic Q fever was started in the southeast region of Noord-Brabant. In total, 763 patients were tested using an IgG phase II indirect fluorescent antibody test (IFAT), of which 52 (7 %) patients tested positive. Ten of these 52 patients displayed a chronic Q fever serological profile. All of these 10 patients had a heart valve(s) or (endo-)vascular prosthesis. All except one were asymptomatic. Suggestive signs for chronic infections on positron emission tomography-computed tomography (PET-CT) were demonstrated in 5 (50 %) of these patients. Forty-two out of the 52 patients with a positive screening test showed a past Q fever serological profile. After a year of follow-up (every 3 months), none of these patients showed elevation of antibody titres and no new chronic Q fever patients were found in this group. A targeted screening programme is a useful instrument for detecting patients at risk of developing chronic Q fever.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010905     DOI: 10.1007/s10096-012-1749-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

Review 1.  Natural history and pathophysiology of Q fever.

Authors:  D Raoult; Tj Marrie; Jl Mege
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

Review 2.  Q fever.

Authors:  Neil R Parker; Jennifer H Barralet; Alan Morton Bell
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

3.  Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections.

Authors:  D Raoult; H Tissot-Dupont; C Foucault; J Gouvernet; P E Fournier; E Bernit; A Stein; M Nesri; J R Harle; P J Weiller
Journal:  Medicine (Baltimore)       Date:  2000-03       Impact factor: 1.889

Review 4.  Vascular complications of Q-fever infections.

Authors:  M C A Wegdam-Blans; T Vainas; M R van Sambeek; P W Cuypers; H T J Tjhie; A H M van Straten; J A Teijink
Journal:  Eur J Vasc Endovasc Surg       Date:  2011-05-31       Impact factor: 7.069

5.  Long-term persistence of Coxiella burnetii in the host after primary Q fever.

Authors:  R J Harris; P A Storm; A Lloyd; M Arens; B P Marmion
Journal:  Epidemiol Infect       Date:  2000-06       Impact factor: 2.451

Review 6.  Chronic Q fever: review of the literature and a proposal of new diagnostic criteria.

Authors:  M C A Wegdam-Blans; L M Kampschreur; C E Delsing; C P Bleeker-Rovers; T Sprong; M E E van Kasteren; D W Notermans; N H M Renders; H A Bijlmer; P J Lestrade; M P G Koopmans; M H Nabuurs-Franssen; J J Oosterheert
Journal:  J Infect       Date:  2011-12-23       Impact factor: 6.072

7.  Long-term outcome of Q fever endocarditis: a 26-year personal survey.

Authors:  Matthieu Million; Franck Thuny; Hervé Richet; Didier Raoult
Journal:  Lancet Infect Dis       Date:  2010-07-14       Impact factor: 25.071

8.  The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak.

Authors:  Barbara Schimmer; Ronald Ter Schegget; Marjolijn Wegdam; Lothar Züchner; Arnout de Bruin; Peter M Schneeberger; Thijs Veenstra; Piet Vellema; Wim van der Hoek
Journal:  BMC Infect Dis       Date:  2010-03-16       Impact factor: 3.090

9.  Coxiella burnetii infection of aortic aneurysms or vascular grafts: report of 30 new cases and evaluation of outcome.

Authors:  E Botelho-Nevers; P-E Fournier; H Richet; F Fenollar; H Lepidi; C Foucault; A Branchereau; P Piquet; M Maurin; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-09       Impact factor: 3.267

10.  One-year follow-up of patients of the ongoing Dutch Q fever outbreak: clinical, serological and echocardiographic findings.

Authors:  G J M Limonard; M H Nabuurs-Franssen; G Weers-Pothoff; C Wijkmans; R Besselink; A M Horrevorts; P M Schneeberger; C A R Groot
Journal:  Infection       Date:  2010-09-21       Impact factor: 3.553

View more
  5 in total

1.  Long-Term Serological Follow-Up of Acute Q-Fever Patients after a Large Epidemic.

Authors:  Cornelia C H Wielders; Joris A F van Loenhout; Gabriëlla Morroy; Ariene Rietveld; Daan W Notermans; Peter C Wever; Nicole H M Renders; Alexander C A P Leenders; Wim van der Hoek; Peter M Schneeberger
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

2.  Emergence of Q fever arthritis in France.

Authors:  Emmanouil Angelakis; Sophie Edouard; Marie-Alix Lafranchi; Thao Pham; Pierre Lafforgue; Didier Raoult
Journal:  J Clin Microbiol       Date:  2014-01-15       Impact factor: 5.948

3.  Vascular chronic Q fever: quality of life.

Authors:  J C J P Hagenaars; P C Wever; S O A Shamelian; A S Van Petersen; M Hilbink; N H M Renders; G L De Jager-Leclercq; F L Moll; O H J Koning
Journal:  Epidemiol Infect       Date:  2015-01-22       Impact factor: 4.434

4.  Molecular diagnosis of Coxiella burnetii in culture negative endocarditis and vascular infection in South Korea.

Authors:  Moonsuk Bae; Hyo Joo Lee; Joung Ha Park; Seongman Bae; Jiwon Jung; Min Jae Kim; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Yong Shin; Sung-Han Kim
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

5.  Cost-effectiveness of Screening Program for Chronic Q Fever, the Netherlands.

Authors:  Pieter T de Boer; Marit M A de Lange; Cornelia C H Wielders; Frederika Dijkstra; Sonja E van Roeden; Chantal P Bleeker-Rovers; Jan Jelrik Oosterheert; Peter M Schneeberger; Wim van der Hoek
Journal:  Emerg Infect Dis       Date:  2020-02       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.